Julie Woodward, MD
Ophthalmology · Durham, NCNPI 1134203011
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $296,188 and has fallen 77.0% since, to $68,002 in 2025. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 632 payments — averaging $1599.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$619K
- Galderma Laboratories, L.p.$323K
- Merz North America, Inc.$66K
- Amgen$2K
- Merz Pharmaceuticals, LLC$274
- Biotissue Holdings Inc.$199
- plus $495 from 7 others
Across 36 payments — averaging $1086.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$39K
What the payments were for
- Consulting fees$351,14035%
- Speaking & faculty fees$557,00355%
- Travel & lodging$85,6208%
- Food & beverage$16,9292%
- Education$3220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 410 | $619,282 |
| Galderma Laboratories, L.p. | 164 | $323,087 |
| Merz North America, Inc. | 41 | $65,724 |
| Amgen(2 entities) | 7 | $1,954 |
| Merz Pharmaceuticals, LLC | 2 | $274 |
| Biotissue Holdings Inc. | 1 | $199 |
| Genentech USA, Inc. | 1 | $135 |
| Davol Inc. | 1 | $115 |
| Endo Pharmaceuticals Inc. | 1 | $96 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $67 |
| Incyte Corporation | 1 | $30 |
| Johnson & Johnson | 1 | $26 |
| Stryker | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$232,517
- XEOMIN$51,328
- NATRELLE SALINE-FILLED BREAST IMPLANTS$25,211
- Venclexta$4,225
- KYBELLA$1,950
- TEPEZZA$1,700
- DYSPORT$481
- BOTOX COSMETIC$240
- ASCLERA$147
- Erivedge$135
- Phasix Mesh$115
How this compares
$1,011,014 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 27 | $319 |
| Clonazepam | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Durham
- Lejla VajzovicDurham$681K
- Terry KimDurham$605K
- Leon HerndonDurham$230K
- Glenn JaffeDurham$218K
- Robin VannDurham$213K
- Anthony KuoDurham$186K
- Michael RichardDurham$113K
- Priyatham MettuDurham$111K
- Jason LissDurham$69K
- Majda HadziahmetovicDurham$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.